跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NT-100
首页
药物
NT-100
NT-100
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
SPIDER SILK FUSION PROTEIN STRUCTURES FOR BINDING TO AN ORGANIC TARGET
EP 2632948 A1
申请人: SPIBER TECHNOLOGIES AB
优先权: 2010
CN
EP
US
WO
8 件公开
ENGINEERED SPIDER SILK PROTEINS AND USES THEREOF
EP 3263593 A1
申请人: RISING ANNA
优先权: 2016
CN
EP
US
5 件公开
Charge-reversed N-terminal spider silk protein domain and uses thereof
US 10626152 B2
申请人: SPIBER TECH AB
优先权: 2015
CN
US
3 件公开
EP 3168228 A1
申请人: SPIBER TECH AB
优先权: 2015
EP
Short multi-repeat RNA targeting gene silencing
US 12662670 B2
申请人: UNIV KANSAS STATE
优先权: 2021
US
WO
3 件公开
Pyrimidine derivates, medicaments comprising them, their use and process of their preparation
EP 2332924 A1
申请人: BOEHRINGER INGELHEIM PHARMA
优先权: 2002
EP
Specific base modification antisense nucleotide chain and application thereof
CN 102311956 B
申请人: UNIV ZHEJIANG
优先权: 2011
CN
Composite antibacterial peptide produced by bacillus natto NT-6 and production method thereof
CN 102321182 A
申请人: UNIV GUANGDONG OCEAN
优先权: 2011
CN
一种NT-proBNP重组蛋白的保存液及其制备方法
CN 111848775 B
申请人: 武汉生之源生物科技股份有限公司
优先权: 2020
CN
Reagent for detecting breast cancer axillary lymph node metastasis and application thereof
CN 113398287 A
申请人: GENERAL HOSPITAL OF EASTERN THEATER COMMAND OF THE CHINESE PEOPLES LIBERATION ARMY
优先权: 2021
CN
Poly (A) sequence for optimizing mRNA preparation and expression
CN 119799693 A
申请人: NAMEIXIN SHANGHAI BIOTECHNOLOGY CO LTD
优先权: 2023
CN
第 1 / 2 页
上一页
下一页
药物
反馈